Can we wake and kill sleeping breast cancer cells? new trial aims to find out

NCT ID NCT04841148

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with early-stage ER+ breast cancer who still have hidden cancer cells in their bone marrow after surgery and standard therapy. It tests whether adding drugs like hydroxychloroquine or avelumab, with or without palbociclib, can clear those leftover cells and lower the risk of the cancer coming back. About 96 participants will be assigned to different treatment groups to see which approach works best and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Georgetown University
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Indiana University
RECRUITING

Indianapolis, Indiana, 46202, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Email: •••••@•••••
University of Washington
RECRUITING

Seattle, Washington, 98195, United States
Vanderbilt University
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.